Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.



<ul>
<li>B of A Securities analyst Tim Anderson upgraded Bristol-Myers Squibb Co (NYSE:BMY) from Neutral to Buy and raised the price target from $52 to $61. Bristol-Myers Squibb shares closed at $52.41 on Friday. See how other analysts view this stock.</li>



<li>BTIG analyst Gregory Lewis upgraded EnerSys (NYSE:ENS) from Neutral to Buy and announced a $175 price target. EnerSys shares closed at $147.26 on Friday. See how other analysts view this stock.</li>



<li>Keybanc analyst Jackson Ader upgraded the rating for Zoominfo Technologies Inc (NASDAQ:GTM) from Underweight to Sector Weight. ZoomInfo shares closed at $9.96 on Friday. See how other analysts view this stock.</li>



<li>Keybanc analyst Jackson Ader upgraded Asana Inc (NYSE:ASAN) from Sector Weight to Overweight and announced a price target of $18. Asana shares closed at $14.35 on Friday. See how other analysts view this stock.</li>



<li>Keybanc analyst Jackson Ader upgraded Akamai Technologies Inc (NASDAQ:AKAM) from Underweight to Overweight and boosted the price target from $66 to $115. Akamai shares closed at $85.88 on Friday. See how other analysts view this stock.</li>
</ul>



Considering buying BMY stock? Here’s what analysts think: 



<figure class="wp-block-image size-large is-resized"></figure>



Read This Next: 



<ul>
<li>Top 2 Energy Stocks That May Plunge This Month</li>
</ul>



Photo via Shutterstock

ASAN

AKAM

Top Wall Street analysts upgraded several stocks. B of A Securities' Tim Anderson upgraded Bristol-Myers Squibb (NYSE:BMY) from Neutral to Buy, raising the price target to $61. BTIG's Gregory Lewis upgraded EnerSys (NYSE:ENS) to Buy with a $175 price target. Keybanc's Jackson Ader upgraded Zoominfo Technologies (NASDAQ:GTM) to Sector Weight, Asana Inc (NYSE:ASAN) to Overweight with an $18 price target, and Akamai Technologies (NASDAQ:AKAM) to Overweight with a $115 price target.

benzinga_article

This Bristol-Myers Squibb Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday